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The close integration of the MAPK, PI3K and WNT signaling
pathways underpins much of development and is deregulated in
cancer. In principle, combinatorial post-translational modiﬁcation
of key lineage–speciﬁc transcription factors would be an effective
means to integrate critical signaling events. Understanding how
this might be achieved is central to deciphering the impact of mi-
croenvironmental cues in development and disease. The microph-
thalmia associated transcription factor, MITF, plays a crucial role in
the development of melanocytes, the retinal pigment epithelium,
osteoclasts and mast cells, and acts as a lineage survival oncogene
in melanoma. MITF coordinates survival, differentiation, cell cycle
progression, cell migration, metabolism and lysosome biogenesis.
Yet how the activity of this key transcription factor is controlled
remains poorly understood. Herewe show that GSK3, downstream
from both the PI3K and Wnt pathways, and BRAF/MAPK signaling
converge to control MITF nuclear export. Phosphorylation of the
melanocyte MITF-M isoform in response to BRAF/MAPK signaling
primes for phosphorylation by GSK3, a kinase inhibited by both
PI3K and Wnt signaling. Dual phosphorylation, but not mono-
phosphorylation, then promotes MITF nuclear export by activat-
ing a previously unrecognized hydrophobic export signal. Non-
melanocyte MITF isoforms exhibit poor regulation by MAPK sig-
naling, but instead their export is controlled by mTOR.We uncover
here an unanticipated mode of MITF regulation that integrates
the output of key developmental and cancer-associated signaling
pathways to gate MITF ﬂux through the import-export cycle.
The results have signiﬁcant implications for our understanding of
melanoma progression and stem cell renewal.
MITF j melanoma j MAPK j nuclear export j GSK3
Introduction
The ability of transcription factors to respond to distinct signal
transduction pathways and thereby implement gene expression
programs characteristic of specific cell identities underpins de-
velopment and is deregulated in disease. However, the output
of discrete signaling modules should be integrated if complex
microenvironmental cues are to be coordinated with cell behavior
and the adoption of particular phenotypic states. This implies that
those transcription factors with a key role in coordinating many
aspects of cell biology may act as a nexus for multiple signaling
pathways, integrating their output to fine-tune the expression of
specific repertoires of target genes. Identifying how such master-
regulators of cell phenotype respond and coordinate multiple
signaling inputs is key to deciphering the impact of signaling in
development and disease.
The MITF gene encoding the microphthalmia-associated
transcription factor not only determines cell identity in devel-
opment, but resides at the heart of melanocyte and melanoma
biology where it coordinates a remarkably wide range of cell
functions. MITF is a lineage survival oncogene (1) that coop-
erates with BRAF in melanoma initiation (2). It is required for
melanoblast (3) and melanoma (4) survival and differentiation
(5), but inhibits invasiveness (6) and tumor-initiation capacity
(7). MITF has both a positive and negative role in cell division,
promoting a differentiation–associated cell cycle arrest (5) but
also driving proliferation (6, 8). The positive and negative roles
in melanoma and melanocyte proliferation have been explained
by the so-called rheostat model forMITF function in which its ex-
pression and activity increase as cells progress from invasiveness,
through proliferation to differentiation (6, 9). Consistent with
this, MITF is repressed by stresses that reprogram translation
and drive invasion and drug and immunotherapy resistance (10).
This model appears broadly to explain the correlations between
MITF expression and invasiveness and proliferative phenotypes
in melanoma. In addition, both low and high MITF have been
associated with drug resistance (11-14), and siRNA-mediated
depletion of MITF in melanoma triggers senescence (15). MITF
has also been implicated in the biogenesis of both lysosomes
Signiﬁcance
Signaling pathways ultimately exert their inﬂuence on cell
behavior by regulating the activity of transcription factors that
drive gene expression programs associated with speciﬁc cell
phenotypes. How transcription factors integrate the outputs
from multiple independent signaling events to coordinate cell
behavior is a key issue. Here we identify a novel regulated
nuclear export signal in the lineage survival oncogene and
cell fate-determining factor MITF. The regulated export signal
integrates the outputs from theMAPK signaling pathwaywith
those regulating GSK3 that play key roles in development
and disease. The regulation of MITF nuclear export provides
a means by which these key signaling pathways tune MITF
activity that in turn controls cell identity in development and
disease.











































































































































Fig. 1. GSK3 phosphorylates MITF S69 to control MITF subcellular localization (A) MITF post-translational modiﬁcations. (B) Immunoﬂuorescence of
SKmel28 cells following treatment with 1 μM BIO or DMSO for 18 h. Cells were stained with DAPI (blue) and antibodies against MITF (green) orβ-catenin
(red).Quantiﬁcation (right). n >70 per condition. Error bars represent SEM. 2-tailed t-test: **** p<0.0001.(C)Western blot of SKmel28cells following treatment
with 1 μM BIO, 1 μM of SB-675259-M or DMSO as in A. (D) Amino acid sequence alignment of MITF. In the GSK3 consensus X = any amino acid.(E) Left panel,21
residue peptides corresponding to MITF amino acids 61 to 81used for the SPOT kinase assayimmobilised on a cellulose support membrane.Middle panel, spot
kinase assay using puriﬁed GSK3β. A map showing the identity of the 10 tested peptides (left) corresponding to peptide spots on the membrane imaged
in UV light (middle), and the kinase assay (right). (F)Western blot of 501mel cells ectopically expressing indicated MITF-FLAG WT and mutants. (G) Western
blot of extracts from 501mel cells ectopically expressing indicated MITF-FLAG WT and mutants treated or not with calf intestinal phosphatase (CIAP).(H, I)
Fluorescence images of 501mel cells ectopically expressing GFP-MITF WT and indicated mutants (green). Scale bars indicate 10 μm. Quantiﬁcation (right). n>40
per condition. Error bars represent SEM. 2-tailed t-test (upper) and one-way ANOVA with post-hoc Tukey test: **** p<0.0001, NS (not signiﬁcant) p>0.05.
(J)Luciferase assay with MITF-FLAG WT and mutants and a TYR promoter-Luc reporter co-transfected into in HeLa cells. Error bars represent SEM. 2-tailed
t-test: **** p<0.0001.Western blot shows relative expression of WT and mutant MITF-FLAG proteins.
(16, 17) and mitochondria (18, 19), thereby contributing to both
autophagy and metabolism. Beyond melanocytes and melanoma,
MITF is transcribed from alternative promoters generating iso-











































































































































Fig. 2. BRAF/MAPK signalling redirects MITF to the
cytoplasm (A) Western blot or (B) Immunoﬂuores-
cence of 501mel cells following 200 nMTPA treatment
(1 h) in the presence or absence of 10 μM U0126 (3
h).After ﬁxation and permeabilisation, the cells were
stained with the nucleic acid stain DAPI (blue) and
antibodies againstMITF (green) or phospho-ERK (red).
n >100 for each condition. (C) Immunoﬂuorescence
of 501 mel cells treated with 200 nM TPA (1h) and/or
1 μM BIO. n>40 cells per condition. (D) Fluorescence
assay of 501mel cells ectopically expressing WT or
mutant MITF-GFP and treated with 200 nM TPA for
1 h as indicated. n 49 > for each condition. (E) Im-
munoﬂuorescence of Flip-in HeLa cells engineered to
express Doxycyclin-inducible BRAFV600E-FLAG ectopi-
cally expressing GFP-MITF WT or the S73A mutant
(green). 24 h post-transfection, cells were treatedwith
2 ng/mL doxycycline for 24 h and treated as indicated
with 10 μM of U0126 for 3 h. Anti-FLAG-BRAF (red).
n>10 cells per condition. Quantiﬁcation by 2-tailed
t-test or one-way ANOVA with post-hoc Tukey test
(E):* p<0.05; ** p<0.01***; p<0.001; **** p<0.0001;
NS (not signiﬁcant) p>0.05; Error bars represent SEM.
promote differentiation of the retinal epithelium, osteoclasts and
mast cells (3), and recently have been implicated in proliferation
of pancreatic ductal adenocarcinoma (21).
Given the critical role of MITF in so many aspects of devel-
opmental and cancer biology, understanding whether and how it
might integrate the output from the complexmicroenvironmental
cues encountered by cells in development or in tumors is a
key issue. Several post-translational modifications of MITF have
been identified to date, but the role of many is poorly understood.
MITF is sumoylated at two sites, K182 and K316 (22-25), which is
thought to promote differential target specificity. Importantly the
MITF E318K mutation that prevents sumoylation on K316 pre-
disposes tomelanoma (24, 25), confirming the pro-oncogenic role
of MITF. In addition to sumoylation, MITF is modified by sev-
eral kinases. These include the mitogen-activated protein kinase
(MAPK) ERK2 and RSK, with ERK-mediated phosphorylation
on S73 reported to mediate increased binding to the p300 and
CBP transcription cofactors (26) as well as ubiquitin-mediated
degradation (27, 28). In osteoclasts, the stress-activated kinase
p38 phosphorylates MITF on S307 to facilitate activation of gene
expression (29), whereas phosphorylation of non-melanocyte iso-
forms by TAK1 (30) or mTOR (31) mediates cytoplasmic re-
tention via binding to a 14-3-3 protein. Whether p38, TAK1 or
mTOR are MITF kinases in melanocytes/melanoma is unknown.
GSK3, which is inhibited by both PI3K and Wnt signaling, has
been reported tomodify S298 to influenceDNAbinding (32), and
more recently three C-terminal GSK3 sites have been implicated
in controlling MITF protein stability (17). Whether and how
other signals control MITF activity through post-translational
modification is unknown.
Here we reveal that critical developmental signaling pathways
already known to promote tumor initiation and senescence bypass
in melanoma converge to control an ERK and GSK3-regulated
MITF nuclear export signal that regulates flux through the nu-
clear import-export cycle.
Results
In different tissues and cell types MITF expression is controlled
by distinct promoters leading to the inclusion of different exons
at the N-terminus of the protein (20). In neural crest-derived
melanocytes and melanoma the MITF-M isoform predominates
and is referred to here as MITF. Although many groups have
focused on how changing MITF levels affect its function, the
activity of MITF will also be influenced by its post-translational
modifications. Yet despite several post-translational modifica-
tions on MITF being identified (Fig. 1A), few have been assigned
a clear regulatory function. Post-translational modifications can
potentially control transcription factor activity by regulating their
levels, interaction with co-factors, intra-molecular conformation,
DNA-binding affinity, or intracellular localization. To identify ad-
ditional kinases that might affect MITF expression or subcellular
localization we undertook a phenotypic screen of SKmel28 hu-
manmelanoma cells using a 367 compound small molecule kinase
inhibitor library (33). Cells were treated with 2.5 μM of each
compound and examined 6 h later using an anti-MITF antibody











































































































































Fig. 3. MITF has a nuclear export signal (A)
Alignment of MITF sequences in the vicinity of
S69 and S73 from different species. Hydrophobic
residues highlighted in blue indicate the putative
NES.(B)Immunoﬂuorescence of endogenous MITF in
501mel cells treated with 20 nM LMB for 3 h as
indicated. n>80 cells per condition. (C) Fluorescence
images of 501mel cells ectopically expressing wild-
type GFP-MITF (green) treated with 200 nM TPA for
1 h and/or 20 nM LMB for 3 h. n>49 per condition.
(D) CRM1 pull down assay using bacterially expressed
HIS-Tagged MITF (1-105) bound to Ni-NTA beads. All
proteins were bacterially expressed and puriﬁed and
after pull-down CRM1 and RAN were detected by
Western blotting using speciﬁc antibodies. Puriﬁed
MITF was visualised by Coomassie staining (lower
panel). (E-F) Fluorescence assay of 501mel cells trans-
fected with indicated GFP reporters. n>43 per condi-
tion. Quantiﬁcation by 2-tailed t-test: ***, p<0.001;
**** p<0.0001; NS (not signiﬁcant) p>0.05; Error bars
represent SEM.
Fig. 4. Regulated nuclear export of MITF-A isoforms. (A) Immunoﬂuores-
cence using anti-MITF antibody of HeLa cells transfected with expression
vectors for MITF-A isoform treated with indicated drugs (20 nM LMB; 10 μM
of U0126; 200 nM Torin 1; 1 μM BIO) or expressing the L80A mutant.n>20
cells per condition.(B)Immunoﬂuorescence using anti-MITF of ARP19 (RPE)
cells with or without 20 nM LMB. n>20 cells per condition.Scale bars indicate
10 μm. Quantiﬁcations by 2-tailed t-test: ***, p<0.001; **** p<0.0001; NS
(not signiﬁcant) p>0.05; Error bars represent SEM.
staining and themean intensity of nuclearMITFwere normalised
relative to a corresponding DMSO-treated internal control. The
preliminary results indicated that compounds targeting GSK3 (SI
Appendix, Fig. S1A) promoted increased MITF nuclear accu-
mulation at the expense of weak cytoplasmic staining that was
reproducibly observed using different MITF antibodies. As an
example, BIO, a selective, ATP-competitive inhibitor of GSK3
(34) increased MITF nuclear localization (Fig. 1B). β-catenin,
which is degraded in response to GSK3−mediated phosphoryla-
tion was used as a control. Similar results were obtained using SB-
675259-M, a chemically distinct GSK3 inhibitor (SI Appendix,
Fig. S1B). GSK3 is important as it is inhibited by PI3K signaling
that is frequently activated in melanoma either through PTEN
loss or via activating mutations in the PI3K catalytic subunit
(35). In melanoma, PI3K signaling inhibits GSK3 activity and
promotes resistance to anti-BRAF inhibitor therapies (36) and
senescence bypass (37). GSK3 is also inhibited byWNT signalling
that stabilises β-catenin that can also promote senescence bypass
in melanoma (38). Consistent with GSK3 targeting MITF both
the GSK3 inhibitor BIO or the structurally distinct GSK3 in-
hibitor SB-675259-M causedMITF to migrate at an intermediate
position between the known hypo-phosphorylated lower form,
and the upper band that is known to be phosphorylated on S73
by ERK (39) when analysed by SDS PAGE and western blotting
(Fig.1C).
One interpretation of these data is that phosphorylation by
ERK on S73 promotes phosphorylation by GSK3 on another
residue. As such, mutation of S73 would prevent phosphorylation
by both kinases, but GSK3 inhibition would not affect phospho-
rylation by ERK. This model is attractive since GSK3 frequently
requires a priming phosphorylation site; the consensus recogni-
tion motif for GSK3 is S-X-X-X-pS, with the first serine being











































































































































Fig. 5. MITF S69 is required for melanocyte development (A) Representative
images of mitfa-null nacreembryos injected with plasmids encoding Mitfa
WT or indicated mutants taken 5 days post fertilisation (dpf). (B) Quan-
tiﬁcation of the number of rescued melanocytes per embryo. Mitfa wild-
type (number of embryos n = 11, mean melanocytes per embryo = 9.9);
S69A mutant (number of embryos = 29, mean number of melanocytes per
embryo = 6.1); S69E number of embryos = 25, mean = 0). For WT vs S69A:
no signiﬁcant difference by one-way ANOVA test (95% conﬁdence interval:
[-0.876, 8.418]).
serine at the +4 position (40). Examination of the MITF amino
acid sequence in the vicinity of S73 revealed a potential GSK3
phosphorylation site at S69 that was evolutionarily conserved
from zebrafish to humans (Fig.1D).Moreover, a large-scale phos-
phoproteome analysis previously identified both S69 and S73 as
being phosphorylated (41), though the nature of the relevant
kinases and implications of phosphorylation were not examined.
In this respect, the spacing between the ERK phosphorylation
site at S73 and the GSK3 site at S69 matched the consensus and
implied that ERK would act as the priming kinase.
This was confirmed using an in vitro kinase assay on a series
of WT and mutated MITF peptides spanning S69 and S73 (Fig.
1E). Only peptide 6 containing an intact S69 as well as p-S73 was
phosphorylated by purified GSK3β . A peptide (Peptide 7) con-
Fig. 6. . Model illustrating potential regulation of MITF nuclear export.
taining a substitution of S73 by a glutamic acid, frequently used
to mimic phosphorylation, was not phosphorylated by GSK3β ,
highlighting the specificity of the S73 phosphorylation event in
priming for GSK3β.
The results obtained using the peptide kinase assay were
confirmed using a quantitative Mass Spec (MS) approach in
which the bacterially expressed and purified N-terminal domain
of MITF (SI Appendix, Fig. 2A) was subject to phosphorylation
in vitro using ERK and GSK3β alone or together (SI Appendix,
Fig. 2B-E). Quantification (SI Appendix, Fig. 2F) revealed that
while ERK phosphorylated S73 but not S69, the modification of
S69 by GSK3β was inefficient unless S73 was phosphorylated.
Western blotting of extracts from cells expressing WT and
mutant MITF further substantiated our conclusion that phos-
phorylation of S73 primes for GSK3-mediated phosphorylation
at S69. Mutation of S69 led to MITF adopting an intermediate
mobility (Fig. 1F), similar to that observed using GSK3 inhibitors
(Fig. 1C), whereas mutation of S73, as predicted, led to a com-
plete shift to the lower position. No effect on MITF mobility was
detected after mutation of S298 that has previously been reported
as a GSK3 target (32). Both the upper and lower bands were
shifted down if the three C-terminal GSK3 sites identified by
Ploper et al. (17) were mutated, though the ratio between the
upper and lower bands was maintained and no substantial effect
on protein levels was observed. Phosphatase treatment of extracts
from 501mel cells transfected with FLAG-taggedWT andmutant
MITF followed by Western blotting led to increased mobility of
MITF to a position below that of the S73Amutant (Fig. 1G). This
result is consistent with MITF being phosphorylated on multiple
residues in addition to S73 and S69, including the C-terminal
GSK3 phosphorylation sites. Note that the charge on the glutamic
acid substitution mutants results in a small reduction in protein
mobility.
Using an MITF–GFP fusion protein expressed in MITF-
negative HeLa cells confirmed that the cytoplasmic fluorescence
detected using the WT protein was abolished by either the S69A
or S73A mutations, whereas mutating either S298 or the C-
terminal GSK3 sites had no effect on MITF localization (Fig.
1H). Moreover, introduction of phospho-mimetic glutamic acid











































































































































of cytoplasmic MITF localization as the WT (Fig. 1I), while the
S69A and S69A, S73A mutants were significantly more nuclear.
Note the S69E mutant was significantly more cytoplasmic than
the S69A mutant, suggesting that S69 may control subcellular
localization. Moreover, the increased nuclear localization of the
S69A and S73A mutants was reflected in their increased capacity
to activate a Tyrosinase-promoter-luciferase reporter (Fig. 1J),
Cytoplasmic accumulation of MITF in response to
BRAF/MAPK signalling
To examine the impact of regulating MAPK signalling on
MITF subcellular localization, we treated 501mel melanoma
cells with 12-O-Tetradecanoylphorbol-13-acetate (TPA). TPA ef-
ficiently promotes ERK phosphorylation and a mobility shift in
MITF consistent with increased phosphorylation on S73, with
both being blocked by the MEK inhibitor U0126 (Fig. 2A). As
anticipated, given the role of S73 phosphorylation in priming
GSK3-mediated modification of S69, TPA increased nuclear-
localization of activated ERK and the proportion of cytoplasmic
MITF, an effect blocked using U0126 (Fig. 2B). MITF cytoplas-
mic accumulation in response to TPA was prevented using the
GSK3 inhibitor BIO (Fig. 2C) as well as by the S73A mutation,
and was reduced using the S69A mutant (Fig. 2D), indicating
that phosphorylation on S73 in the absence of S69 phosphoryla-
tion can make a contribution to MITF’s subcellular localization
independently of its ability to promote S69 phosphorylation.
Similar results were obtained in HeLa cells where induction of
doxycycline-inducible BRAFV600E promoted cytoplasmic localiza-
tion ofWTMITF-GFP (Fig. 2E), which was blocked usingU0126,
but did not trigger cytoplasmic accumulation of the S73Amutant.
MITF contains a BRAF/MAPK-regulated nuclear export sig-
nal
Although TPA induces MITF to be completely phosphory-
lated at S69 and S73 (Fig. 2A), TPA does not induce all endoge-
nousMITF to be localized to the cytoplasm (Fig. 2B). The balance
between cytoplasmic and nuclear localization will be influenced
by several factors including the relative rate of nuclear import
and export. MITF’s nuclear import is mediated by a constitutive
nuclear localization signal in the basic region of the bHLH-
LZ domain (42). Whether MITF is subject to active nuclear
export is not known. Preliminary evidence indicated that the N-
terminal region of MITF (residues 1-180) could re-localize to
the cytoplasm in response to TPA treatment (SI Appendix, Fig.
S3A). Moreover, a series of N-terminal deletionmutants revealed
that TPA was able to promote cytoplasmic localization of MITF
lacking the N-terminal 60 amino acids, but was unable to do
so if an additional 40 amino acids were removed (SI Appendix,
Fig. S3B). Thus residues 60-100, which contain the S69 and S73
regulatory phosphorylation sites, were required for TPA-induced
cytoplasmic localization. Examining the amino acid sequence
in the vicinity of S73, the key regulator of MITF cytoplasmic
accumulation, revealed a hydrophobic patch (MxMLxL) that
resembled a classical nuclear export signal (NES) (43) (Fig. 3A).
We confirmed that MITF is subject to active export from the
nucleus using (LMB), an inhibitor of CRM1-mediated export
(44), which increased nuclear localization of MITF (Fig. 3B) and
prevented cytoplasmic accumulation of MITF-GFP in response
to TPA treatment (Fig. 3C). Consistent with these observations,
MITF was able to directly interact with CRM1 in a RAN-GTP-
dependent fashion in vitro using bacterially expressed and puri-
fied proteins (Fig. 3D) consistent with results from a previous
deep proteomic assay for CRM1 interactions (45).
To determine whether this region of MITF contains a func-
tional NES, we used a GFP-based fluorescent NES reporter
vector. Since the final size of any GFP fusion protein in the
reporter needed to be greater than 40 kDa to prevent passive
diffusion between the cytoplasm and nucleus (46) GST was fused
in frame with GFP. The parental GFP-GST reporter was largely
cytoplasmic (SI Appendix, Figure S4A). The addition of a nuclear
localization signal (NLS), PKKKRKV, from the simian virus 40
(SV40) T-antigen (47), led to the reporter being expressed in the
nucleus. Further addition of a classical NES, LALKLAGLDI,
from the cAMP-dependent protein kinase inhibitor (PKI) (48)
served as a positive control for nuclear export, re-localizing the
NLS-containing reporter protein to the cytoplasm. TPA had no
effect on the localization of any of these proteins. Replacement
of the PKI NES with MITF amino acids 60-99 led to the reporter
being distributed between the nucleus and cytoplasm (Fig. 3E),
but addition of TPA promoted cytoplasmic localization. Consis-
tent with our previous observations, the S73A mutant was un-
responsive to TPA and was localized primarily to the nucleus,
whereas the S69A mutant largely abrogated the increased cy-
toplasmic localization triggered by TPA. Importantly, the MEK
inhibitorU0126 significantly reduced the cytoplasmic localization
induced by TPA, while the reporter was almost completely local-
ized in the nucleus in the presence of LMB irrespective of the
presence or absence of TPA (Fig. 3F). Collectively, these data
are consistent with MITF containing a MAPK and GSK3 co-
regulated NES.
To characterise better the requirements for MITF nuclear
export, we used the same GFP-NLS-GST reporter to analyse
the effect of mutations in the putative hydrophobic NES. Single
alanine substitutions in M75, L78 and L80 all abrogated the
relocalization to the cytoplasm in response to TPA (SI Appendix,
Figure S4B). By contrast mutation of M77 had no effect. The
role of M75, L78 and L80 in nuclear export was confirmed in the
context of full length MITF, where the relocalization of the WT
protein to the cytoplasm in response to TPA was prevented by
alanine substitution in any of these three residues (SI Appendix,
Figure S4C). Importantly, mutation of L75, L78 or L80 did not
affect the ERK-mediated mobility shift in MITF in response to
TPA arising via phosphorylation of S73 (SI Appendix, Figure
S4D).
Regulation of non-melanocyte isoforms
The results so far suggest that phosphorylation of MITF on
S73 by ERK downstream from BRAF triggers GSK3-mediated
phosphorylation of S69 and consequently NES-mediated MITF
nuclear export. In melanoma cells activation of this pathway, by
induction of MAPK activity is response to TPA or of BRAF for
example, leads to an increased proportion of MITF re-localising
to the cytoplasm. However, under standard growth conditions
only 10-20% of endogenous MITF is cytoplasmic, most likely
reflecting the fact that nuclear import is efficient and that the
melanocyte-specific isoform of MITF, MITF-M, is not retained
in the cytoplasm. By contrast, other isoforms of MITF bearing
different first exons arising from differential promoter usage (20)
can localise to the cytoplasm more completely owing to cytoplas-
mic retention following phosphorylation of S173 by TAK1 in os-
teoclasts (30), or by phosphorylation by mTORC1 and the inter-
action with the RAGGTPases at the surface of the lysosome (31).
We therefore examined the impact of inhibiting nuclear export of
the MITF-A and MITF-D isoforms. In both cases transfection
of HeLa cells with MITF-A or MITF–D expression vectors led
to a largely cytoplasmic localization (Fig. 4A, SI Appendix, Fig-
ure S5A). Cytoplasmic retention of the non-melanocyte isoform
MITF-A was prevented by mutation of conserved residues Q62
and L63 within exon B1b (SI Appendix, Figure S5B) that is
required for interaction with the RAG GTPases (31) and by
Torin 1 (Figure S4A), an inhibitor of mTOR that phosphorylates
on an MITF-M S173-equivalent residue to promote cytoplasmic
retention via phosphorylation-mediated 14-3-3 binding.
However, in bothMITF-A andMITF-D nuclear export is also
important since treatment with either LMBor theGSK3 inhibitor
BIO led to increased accumulation ofMITF-A orMITF-Dwithin











































































































































troducing the MITF-M L80A equivalent into the MITF-A and
MITF–D isoforms also substantially increased nuclear retention
of each isoform. Inhibition of MEK using U0126 to reduce
MAPK activity also increased MITF-A and –D nuclear localiza-
tion to a similar extent as BIO, but less than Torin 1, indicating
that ERK-mediated phosphorylation ofMITFmakes a previously
unrecognized contribution to the subcellular localization of non-
melanocyte isoforms.
These observations were confirmed by examining endoge-
nous MITF in both retinal pigment epithelia (RPE) ARPE19
cells, which express multiple non-melanocyte MITF isoforms
(20), and osteoclasts, which express both the MITF-A and -D
isoforms (49). LMB promoted dramatically increased nuclear
localization of MITF in the ARPE19 RPE cell line (Figure 4B)
and in osteoclasts MITF nuclear accumulation was also increased
in response to BIO, U0126, Torin 1 and LMB (SI Appendix, Fig-
ure S5C). The results obtained using LMB reveal that regulated
nuclear export plays a key role in controlling the nuclear avail-
ability of endogenous MITF in these cells. These data indicate
that the nuclear export signal is highly active in different MITF
isoforms. The reason the endogenous MITF-M isoform does not
more efficiently accumulate in the cytoplasm under steady state
conditions is most likely the absence of alternative exon 1B1b
since mutation of the RAG GTPase interaction motif generated
predominantly nuclear MITF-A (SI Appendix, Fig.S5B).
MITF S69 is critical for melanocyte development
To investigate the possibility that S69 was important in
melanocyte development, we mutated the equivalent of the S69
residue in Zebrafish Mitfa to alanine, which prevents phospho-
rylation, or glutamic acid, which can mimic constitutive phos-
phorylation. We then injected plasmids encoding these mutants
under the control of the fish Mitfa promoter into Mitfa-null
nacre zebrafish embryos and determined if the mutants could
rescue melanophore development in these embryos. The re-
sults (Fig. 5A, B) revealed that the S69A mutant could rescue
melanophore development (number of embryos=29,mean num-
ber of melanophores per embryo = 6.1), as did wild-type Mitfa
(n = 11, mean = 9.9). Although there were fewer melanophores
per embryo with the S69A mutant compared to the wild-type,
there were no significant differences between theWT andmutant
variants as determined by one-way ANOVA test (95% confi-
dence interval: [-0.876, 8.418]). On the other hand, the phospho-
mimetic S69E mutant, that exhibits significantly increased cy-
toplasmic localization compared to S69A (Figure 1I) failed to
rescue melanophore development in all injected embryos (n =
26, mean = 0). WT and mutant Mitfa were similarly expressed in
mitfa-null zebrafish embryos (SI Appendix, Figure S6). However,
while there is a clear difference in the ability of the S69A and
S69E mutants to complement the lack of MITF in zebrafish fish,
consistent with the phosphorylation status of S69 in MITF being
critical for melanocyte development, the absence of antibodies
able to recognise MITF or phospho-S69 in fish means that the
role of S69 phosphorylation inMITF nuclear export in this model
requires further validation.
Discussion
Many nuclear export signals have been characterised (43), and
some, like the yeast transcription factor Pho4 (50) or cyclinD1
(51), are regulated by phosphorylation. However, the NES in
MITF is highly unusual in the sense that it acts as a nexus for key
developmental signalling pathways implicated in melanoma initi-
ation and progression (Fig. 6). In the melanocyte-specific MITF
isoform, MITF-M, phosphorylation of S73 by ERK downstream
from BRAF and NRAS primes for phosphorylation of S69 by
GSK3.
Under standard culture conditions GSK3 is active, and con-
sequently it is the priming activity of ERK that dictates whether
the MITF NES operates. Despite the melanoma cells used here
having a BRAFV600E mutation, ERK activity is not maximal and
can be stimulated by TPA leading to increased cytoplasmic local-
ization of MITF-M. However, GSK3 activity can be suppressed
by PI3K signalling that is frequently activated in melanoma, for
example by loss of PTEN. Since both ERK and GSK3-mediated
phosphorylation events are necessary for efficient export to occur,
the MITF export signal potentially provides a route to integrate
MAPK and PI3K signalling with regulation of MITF’s target
genes implicated in both proliferation and differentiation. Mech-
anistically, we view it likely that the hydrophobic MITF nuclear
export signal may be occluded by an intra-molecular interaction
and that the phosphorylation events alter the conformation to un-
mask the export signal. In this scenario a single phosphorylation
event on S73may contribute, but the dual phosphorylation on S73
and S69 will be more efficient, as in fact we observed.
Although the level of endogenous MITF-M observed in the
cytoplasm is relatively low inmelanoma cells in culture, the steady
state ratio of nuclear to cytoplasmic MITF is likely to be less
important than flux through the import-export cycle. For any
transcription factor, nuclear localisation is necessary for it to find
its target genes. The probability of it being able to do so will
depend on its residence time in the nucleus. Activation of the
MITF NES will lead to decreased nuclear residence time and
is therefore likely to diminish the ability of MITF to bind and
regulate its targets. As such, even a 10% increase in the cyto-
plasmic localization may in reality reflect a far greater effect on
productive MITF DNA-binding and gene regulation. Moreover,
phosphorylation of S73 by ERK has been reported to promote
proteasome-mediated degradation ofMITF (27, 28), although we
have not detected any increased expression of an S73A mutant
versus the WT protein. Nevertheless the role of S73 phosphory-
lation in stimulating export raises the possibility that export may
enhance cytoplasmic MITF turnover and consequently the levels
of steady state cytoplasmic MITF may be underestimated.
In contrast to MITF-M where the majority of the protein is
nuclear under standard culture conditions, the non-melanocyte
MITF isoforms that are critically required for development of
mast cells, osteoclasts and the RPE, are predominantly cytoplas-
mic. Since inhibition of the NES using LMB promotes localiza-
tion of MITF-A and -D to the nucleus, it seems that the non-
melanocyte isoforms are constantly passing through the import-
export cycle, with their predominantly cytoplasmic localization
arising as a result of cytoplasmic retention. This occurs because
the non-melanocyte MITF isoforms, but not MITF-M, contain
residues within their N-terminal region that mediate binding to
RAG GTPases at the lysosomal surface where they can be phos-
phorylated by the nutrient sensing mTORC1 complex (31). Phos-
phorylation of non-melanocyte isoforms by mTORC1 at S173
(using MITF-M numbering) will lead to cytoplasmic retention by
promoting interaction with a 14-3-3 protein (30). Consequently,
inhibition of mTOR using Torin 1 or mutation of the RAG-
interacting region leads to their nuclear accumulation. Since
inactivation of mTORC1 via nutrient limitation will lead to nu-
clear accumulation of the non-melanocyte isoforms(31), the NES
identified here will play a key role in restoring cytoplasmic MITF
localization when nutrient levels are restored. However, the bi-
ological reason why the melanocyte-specific MITF-M isoform is
not regulated by mTOR remains unclear. One possibility is that
duringmelanoblast migrationmTOR-mediatedMITF export and
cytoplasmic retention would be incompatible with regulation of
MITF-drivenmelanoblast proliferation, and consequentlyMITF-
M needs to be uniquely perceptive to MAPK signalling.
Although for technical reasons we have been unable to mea-
sure MITF phosphorylation in the fish model, an S69E substitu-
tion inMitfa prevents melanocyte development whereas an S69A











































































































































suggests that the phosphorylation status of S69 may be important
during melanocyte development. We also envisage there may be
two additional scenarios where a regulatedMITF-Mexport signal
may be important.
First, activation of BRAF or NRAS by mutation in primary
melanocytes in vivo would trigger an instantaneous increase in
MAPK signalling and consequently decrease MITF nuclear lo-
calisation by promoting export. Since in primary melanocytes
activating mutations in BRAF or NRAS trigger senescence, it
is possible that the downstream activation of MAPK signalling
would increase MITF export, as we observed following induc-
tion of BRAFV600E expression, thereby preventing MITF driving
proliferation. Since depletion of MITF in cells bearing activated
BRAF triggers senescence (15), these observations are consistent
with a model in which an active MITF NES might pose a barrier
to BRAF-mediatedmelanoma initiation in vivo. Additionalmuta-
tions in signalling pathways leading to inactivation ofGSK3would
prevent MITF export, and consequently complement BRAF acti-
vation by enablingMITF to remain nuclear to stimulate prolifera-
tion. Consistent with this scenario, PI3K (37) andWNT signalling
(38) both inhibit GSK3 and are implicated in senescence bypass
in melanoma (52-54). We also note that GSK3 can be inhibited
by phosphorylation by p90 RSK lying downstream fromERK and
BRAF (55). Although we have not examined the impact of BRAF
activation on GSK3 activity, the possibility that BRAF activation
can lead to inhibition of GSK3 suggests that the MITF export
signal may be also be modulated by the kinetics of RSK activation
in response to different upstream signals.
Secondly, while the MITF-M NES might provide a mech-
anism to protect against cancer initiation, its primary purpose
will be to regulate MITF activity under physiological conditions.
WNT signalling increasesMITF-Mprotein stability by preventing
phosphorylation of the C-terminal GSK3 sites (17), and also in-
creases MITF-M mRNA expression via β-catenin-mediated acti-
vation of theMITF-M promoter (56), an event that commits cells
to a melanocyte lineage fate to generate melanoblasts (57). Our
results suggest inhibition of GSK3 by WNT might also promote
MITF activity by preventing MITF nuclear export. Moreover,
WNT-mediated activation of melanocyte stem cells in the hair
follicle bulge (58) should drive proliferation by both increasing
MITF expression and preventing MITF export. We also note that
a point source of WNT can promote cell division in the plane of
the WNT signal (59), giving rise to two daughter cells with either
highWNT signalling and consequently lowGSK3 activity close to
the source, or lowWNT signalling and highGSK3 in the daughter
cell furthest from the source. In principle this would create two
daughter cells with differential activity of theMITF export signal.
If point sourceWNT signalling occurs in themelanocyte stem cell
niche, the regulated export signal has the potential to decrease
MITF activity in the distal daughter cell, an event that would
facilitate stem cell renewal. While this model is speculative, it
does provide a framework for future studies that investigate the
potential role of the MITF export signal in stem cell renewal.
While we confirmed that MITF is phosphorylated by GSK3
at its C-terminus as described previously (17), we saw no effect
of mutating the reported (32) S298 GSK3 phosphorylation site
on MITF subcellular localization or mobility by SDS PAGE.
Moreover this site is not localized near any putative priming
phosphorylation site that is usually required for GSK3-mediated
phosphorylation. Given that S298 lies at the end of the MITF
leucine zipper and is not able to mediate DNA-contact (60), it
is difficult to understand mechanistically how it can affect DNA
recognition as reported (32). Moreover, in a separate study Grill
et al. (62) showed that the S298A mutation did not have any
significant effect on MITF’s ability to bind DNA or transactivate
the TYR promoter, as well as other downstream targets such as
the TYRP1 andDCT promoters. We therefore feel it unlikely that
S298 represents a bona fide GSK3 phosphorylation site.
Materials and Methods
Cell culture, transfection and chemicals
Established human melanoma cell lines, including 501mel and SK-MEL-
28 (available from ATCC), were grown in Roswell Park Memorial Institute
(RPMI) 1640 media (Invitrogen), supplemented with 10% fetal bovine serum
(FBS) (PAA Laboratories, Pasching, Austria) and 50 units/ml penicillin, 50
μg/ml streptomycin (Invitrogen). Cell lines of non-melanocytic origin, includ-
ing HeLa and Phoenix-AMPHO, were grown in Dulbecco's Modiﬁed Eagle
Medium (DMEM), supplemented with 10% foetal bovine serum and 50
units/ml penicillin, 50 μg/ml streptomycin. All cells were grown in humidiﬁed
incubators at 37°C with 10% CO2. Cell lines used are authentication was
undertaken by EUROFINS using STR proﬁling and mycoplasma screening
conducted monthly.
Osteoclasts were isolated from peripheral blood mononuclear cells
isolated from leucocyte cones (National Blood Service) by density gradient
centrifugation. CD14+ monocytes were positively selected using magnetic
beads (Miltenyi) and seeded onto glass coverslips in α-MEM culture media
(without ribonucleosides/deoxyribonucleosides, Lonza) containing 10% FBS,
L-glutamine (2 mM), penicillin (50 IU/ml) and streptomycin sulphate (50
μg/ml). Cultures were supplemented with macrophage colony stimulating
factor (M-CSF; 25 ng/ml, R&D Systems) and receptor activator of nuclear
factor kappa B ligand (RANKL; 35 ng/ml, produced in house) every 3–4 days.
Mature osteoclasts, considered as multi-nucleated cells containing ≥ 3 nuclei,
formed by day 9.
Transient transfection of DNA was carried out using the FuGENE 6
(Promega, Madison, WI, USA) according to the manufacturer’s instructions.
HeLa Flp-In T-REx cells were maintained as per wild-type HeLa cells, but
with a further supplement of 4 μg/ml blasticidin to maintain TetR expression
and 50 μg/ml zeocin to ensure that the FRT sites were retained. HeLa Flp-In
T-REx cells were co-transfected with the pcDNA5/FRT/TO plasmid expressing
the BRAFV600E under the control of a tetracycline-regulated CMV/TetO2
promoter, and the pOG44 plasmid that expresses the Flp recombinase under
a constitutive CMV promoter at a 3:1 ratio of pcDNA5/FRT/TO to pOG44.
Transfected cells were selected with 200 μg/ml hygromycin and 4 μg/ml
blasticidin. Stable polyclonals were observed after two weeks of antibiotic
selection.
Doxycycline, TPA and LMB were obtained from Sigma-Aldrich, BIO from
Merck, and U0126 and Torin 1 from Cell Signaling Technology (Danvers, MA,
USA).
Expression vectors and site-directed mutagenesis
MITF-FLAG, orMITF-GFP and derivatives weremade by cloning theMITF-
M cDNA into p3xFLAG-CMV-14 (Sigma, Poole, UK), or pEGFP-C1 (Clontech).
The NES reporter was also constructed using pEGFP-C1. BRAFV600E cDNA was
inserted into pcDNA5/FRT/TO (Invitrogen). Point mutations were introduced
using the QuikChange Lightning Site-Directed Mutagenesis (SDM) Kit (Ag-
ilent) according to the manufacturer’s instructions. Details of construction
available on request.
Western blotting
Following SDS-PAGE proteins were transfered to a Protran nitrocellulose
membrane (Whatman, Kent, UK) via electroblotting took place in transfer
buffer (25 mM Tris, 192 mM glycine, 20% methanol) at 70 V for 90 minutes.
The membrane was blocked with 5% skimmed milk in 0.1% Tween in PBS
(PBST) for 1 hour at room temperature, after which it was incubated with
the primary antibody (typically diluted 1:2000 in 5% milk in PBST) at 4°C
overnight with gentle agitation on a rocking platform. The membrane was
then washed 3 times with PBST for 5 minutes each time and incubated
with the corresponding horseradish peroxidase (HRP)-conjugated secondary
antibody (Bio-Rad) (diluted 1:5000 in 5% milk in PBST) for 1 hour at room
temperature, before another 3x 5-minute wash in PBST. Finally, enhanced
chemiluminescence (ECL) reagent (Amersham, Uppsala, Sweden) was added
and the signal detected with X-ray ﬁlm (Fujiﬁlm, Tokyo, Japan).
Antibodies
Rabbit anti-β-catenin (ab2365, Abcam) ; mouse anti-FLAG (monoclonal
M2, Sigma); rabbit anti-ERK (C14, Santa Cruz); mouse anti-MITF (mono-
clonal AS9, in house); rabbit anti-phospho-ERK (Cell Signaling); rabbit anti-
phospho-β-catenin (Cell Signaling), anti-CRM1 (Santa Cruz); anti-RAN (BD
Biosciences)
Immunoﬂuorescence and Kinase inhibitor screen
Cells were grown to 80% conﬂuence on glass coverslips (VWR, Radnor,
PA, USA). and ﬁxed with 3.7% paraformaldehyde (PFA) (Sigma-Aldrich),
dissolved in PBS and adjusted to pH 7.4, for 15 minutes. After 30 minutes
blocking and permeabilisation with 0.1% Triton-X and 1% BSA in PBS,
cells were incubated with primary antibody (diluted 1:500 in 1% BSA in
PBST) at 4°C overnight with gentle agitation on a rocking platform. After
washing 3 times with PBST for 5 minutes each time, the cells were incubated
with the appropriate Alexa Fluor-conjugated secondary antibody (Invitro-
gen) (diluted 1:1000 in 1% BSA in PBST) for 1 hour, before another 3x
5-minute wash in PBST. DNA was stained with 300 nM 4’,6-diamidino-2-
phenylindole (DAPI) (Invitrogen) in PBS for 15 minutes, before a 3x 5-minute











































































































































with Vectashield Mounting Medium (Vector Laboratories, Burlingame, CA,
USA) before sealing with nail polish. Images were acquired using an LSM710
confocal microscope (Carl-Zeiss, Jena, Germany).
For cells expressing ﬂuorescent proteins, cells were stained with DAPI
after PFA ﬁxation. Blocking, permeabilisation and antibody staining steps
were omitted unless detection of non-ﬂuorescent proteins were required.
The coverslips were then mounted and imaged as above.
For the small molecule library screen, approximately 5,000 SKmel28
melanoma cells were seeded into eachwell of 96-well black CellCarrier plates
(PerkinElmer, Waltham, MA, USA) with optically clear plastic bottoms. Cells
were grown to 80% conﬂuence overnight, upon which they were treated
for 6 hours with 2.5 μM of each compound from the Glaxo Smith Kline (GSK)
Published Kinase Inhibitor Set. Cells were then processed as described in the
immunoﬂuorescence protocol.
The quantiﬁcation of (immune)ﬂuorescence images was performed
using ImageJ. Nuclear masks were created by DAPI staining, and cytoplasmic
masks by either Phalloidin or Cell Tracker Orange (Thermo Fisher). Percent-
age of nuclear MITF intensity was calculated by (MITF in Nucleus)/(MITF in
Whole Cell) x 100% on a per cell basis. Three independent experiments
were performed for each quantiﬁcation with a minimum of 40 cells. ****:
p<0.0001, ***: p<0.001, **: p<0.01, *: p<0.05, NS: non-signiﬁcant.
SPOT kinase assay
21 residue-long peptides corresponding to MITF residues 61 to 81, and
incorporating various mutations and modiﬁcations, were immobilised on a
cellulose support membrane. The membrane was then incubated with 100
ng of puriﬁed GSK3β kinase (New England Biolabs), and 5 µCi [γ-32P]-ATP at
30°C for 30 minutes. After washing, incorporation of 32P was detected by
phosphoimager. The membrane was imaged in UV light to show the relative
size of the peptide spots.
Bacterial expression of TFEB and in vitro phosphorylation
Recombinant 6x HIS-Tagged MITF (1-100) was expressed in E. coli
(Rosetta) by adding 0.1 mM IPTG and incubating overnight at 18˚C. After
harvesting cells were lysed in a buffer containing 6 M urea, 25 mM HEPEs
pH 7.5, 0.5 M NaCl, 5% Glycerol, 20 mM Imidazole, buffer pH 7.5 using
a French Press homogeniser. After centrifugation of the lysate at 25,000g
for 15 min, the supernatant mixed with Ni-NTA agarose beads (QIAGEN),
incubated at 4˚C while rotating for 1 h and then placed in a gravity-ﬂow
column. Beads were then washed twice with wash buffer (6 M urea, 25 mM
HEPEs pH 7.5, 0.5 M NaCl, 5% Glycerol, Buffer pH 7.5) and once with Lysis
Buffer before bound protein was eluted stepwise using Imidazole (50-250
mM). Puriﬁed MITF was visualised by SDS-PAGE and Coomassie staining and
protein-containing fractions pooled and dialysed against buffers containing
buffers decreasing concentrations of urea (25 mM HEPEs pH 7.5, 0.5 M NaCl,
5% Glycerol, 4.0-0.0 M Urea) at 4˚C After dialysis, samples were ﬂash frozen
in aliquots in liquid nitrogen and stored at -80˚C before use.
To phosphorylate MITF in vitro, 2 μg of recombinant HIS-tagged MITF
(1-100) was incubated 1 h at 37˚C with 0.3 mM 100 ng of GSK3β (Abcam)
and/or ERK2 (Sigma Aldrich) in the presence of cold ATP in a reaction diluted
to 22 μl with Kinase Dilution Buffer (5 mM MOPS pH 7.2, 5 mM MgCl2, 0.4
mM EDTA, 1 mM EGTA, 2.5 mM glycerol 2-phosphate) before adding DTT
to a ﬁnal concentration of 0.25 mM. When both ERK and GSK3β were used,
ERK2 was used ﬁrst and GSK3β added after 30 min. Re actions were stopped
by addition of 100 mM EDTA.
Proteomics analysis
Proteins phosphorylated in vitro were subjected to SMART digest
(Thermo Fisher) treatment according to the manufacturer’s instructions,
desalted using SepPak reversed phase columns, and injected into an LC-
MS/MS platform (Dionex Ultimate 3000 nano LC and Orbitrap Fusion Lumos).
Sample separation was undertaken using a 50 cm long EasySpray column
(ES803, Thermo Fisher) with a 75 µm inner diameter and a gradient of 2-
35% acetonitrile in 0.1% formic acid and 5% DMSO with a 250 nl/min ﬂow
rate for 60 min. MS1 spectra with a resolution of 120.000 and an ion target
of 400.000 were acquired, followed by a top speed duty cycle of up to 3
seconds for MS/MS acquisition. Precursor ions isolated in the quadrupole
with a mass window of 1.6 Th were fragmented with HCD@28% normalized
collision energy.MS/MS datawere acquired in the ion trap in rapid scanmode
and an ion target of 4000. PEAKS Server V.7 (Bioinformatics Solutions) and
a Uniprot/Trembl database were used to analyze the LC-MS/MS data set to
identify Phosphorylation (S, T, Y), as well as Oxidation (M) and Deamidation
(N, Q). Mass tolerance was 10 ppm for precursor and 0.5 Da for fragment
mass with a peptide level false discovery rate set to 1%. Freestyle 1.3 (Thermo
Fisher) was used to generate extracted ion chromatograms of relevant
peptides that were quantiﬁed after Gaussian smoothing (3 data points).
MITF-CRM1 interaction assay
N-terminally GST-Tagged CRM1 was expressed in E. coli after induction
overnight at 18°C with 0.5 mM isopropyl-β-D-thiogalatopyranoside (IPTG)
and puriﬁed at 4°C using glutathione beads from extracts of sonicated
bacteria that had been pre-cleared by centrifugation at 50,000 g for 30 min
at RT. Puriﬁed protein was released from the beads by cleavage using TEV
protease. Recombinant CRM1was then further puriﬁed using a MonoQ HP
column and eluted using a 0-1 M NaCl gradient in a buffer containing 20
mM Tris (ph&.5, 1 mM EGTA, 2 mM MgAc, 1 mM DTT and 10% glycerol.
Human HIS-tagged RAN protein was similarly expressed in E. coli, but was
puriﬁed by afﬁnity chromatography on Nickel-NTA beads. Bound RAN was
eluted using 500 mM imidazole and subsequently puriﬁed usinga Superdex-
75 column (Amersham Biosciences) in 20 mM Tris (pH 8.0), 1 mM DTT 10%
(vol/vol) glycerol. To obtain a GTP-bound fraction puriﬁed Ranwas incubated
with GTP at a 1,000 molar-excess in 50 mMHepes pH 7.5, 10 mM EDTA, 4 mM
DTT, 2 mM ATP at 30°C for 30 min, before the reaction was halted using 15
mM MgCl2 at 4°C.
HIS-tagged amino acids 1-105 of the MITF-M isoform expressed in E. coli
cells was expressed as described for RAN. After sonication in denaturing lysis
buffer (50 mM Hepes (pH 7.5), 500 mM NaCl, 20 mM Imidazole, 5% (vol/vol)
glycerol, 10 mM β-mercaptoethanol, 6M Urea), MITF protein was isolated by
direct binding to Ni-NTA beads. The bead were then washed extensively, and
bound protein refolded by stepwise decreasing the Urea concentration from
6 M to 0 M using in volumes of 10 mL and a 1 mL/min ﬂow rate. 100 pmol of
MITF protein bound to Ni-NTA beads was used together with 50 pmol CRM1
with or without a twofold molar excess of GTP-bound Ran. Proteins were
mixed in 400 μL in binding buffer comprising 20 mM Hepes (pH 7.5), 2 mM
magnesium acetate, 110 mM potassium acetate, 1 mM EGTA, 20 mM DTT,
0.005% Nonidet P-40, 20mM Imidazole, and rotated for 2 h at 4 °C. Beads
were washed four times with binding buffer to remove unbound protein
before addition of hot Laemmli buffer. Protein complexes were analyzed by
SDS-PAGE, and CRM1 and RAN detected using by Western blotting.
Zebraﬁsh
2 nl plasmid DNA containing the zebraﬁsh mitfa gene promoter (61)
driving WT and mutant ﬁsh MITF cDNA (70 ng/ul) together with Tol2 mRNA
(70 ng/ul) was injected into mitfa-null nacre embryos at the 1-cell stage and
grown at 28°C for 5 days. Embryos were then exposed brieﬂy to white light
to contract melanocytes and subsequently imaged before ﬁxation in 4% PFA.
The surface melanocytes in the head, trunk and yolksac were then counted.
Quantitative analysis of melanocyte development in groups of ﬁsh injected
with different mutant forms of MITF was carried out with the Minicab 16
statistical software (Minitab Inc, State College, Pennsylvania, USA). 2-sample
T-test was used to determine the difference between two groups. For imag-
ing expression of Mitfa, VC7 embryos (61) were grown for 24 h post-injection
and processed for immunostaining using anti-FLAG antibody (Sigma, F7425,
Rabbit 1:150) and Rabbit AlexaFluor 488-conjugated secondary antibody
(1:250) before visualization using a Leica confocal SP5 microscope at 10x
magniﬁcation. For quantiﬁcation of mitfa gene expression at 24 hpf by RT
PCR, nacremutant ﬁsh have a pointmutation C>T at position 337 in theMitfa
open reading frame, resulting a premature TAA stop codon and truncated
Miitfa protein. To distinguish transgenicmitfa from endogenous nacremitfa,
the last G nucleotide at the 3’ end of the reverse primer differs between
wildtype and nacre so as not to amplify the mutant allele. The sequences
of mitfa primers used for both RT-PCR and q-PCR are: mitfa-F: 5’-CGCCGAG-
CACGGCATGACC-3’ mitfa-WT-R: 5’-TGAAACTGGAATCGTGTTTGTCATTTG-3’.
The size of product is 193bp. Zebraﬁsh β-actinwas used as an internal control.
The primer sequences for β-actin are: actin-F 5’-TGCCATGTATGTGGCCATCCA-
3’ actin-R:5’-ACCTCCAGACAGCACTGTGT-3’ with an amplicon of 602bp, if
there is genomic DNA contamination, an additional amplicon of 689bp will
be seen. For reproducibility the Zebraﬁsh experiments repeated 3 times and
were approved by the University of Edinburgh Animal Welfare and Ethical
Review Body and undertaken in accordance with the Animals (Scientiﬁc
Procedures) Act 1986. Zebraﬁsh lines were bred, raised and maintained as
described (63).
Sub-cellular fractionation
To separate out the cytosolic components of the cell from the nuclear
fraction, trypsinised cells were lysed in cold Triton X lysis buffer (50mMTris-Cl
pH 7.5, 137.5 mMNaCl, 0.5% Triton X-100, 10% glycerol) supplemented with
1x Complete Protease Inhibitor and 1x PhosSTOP Phosphatase Inhibitor. The
cell lysate was incubated on ice for 20 minutes, then centrifuged at 16000 g
and 4°C in a bench-top centrifuge for 15 minutes. The supernatant was the
cytoplasmic fraction while the pellet was resuspended in 1x Laemmli sample
buffer and taken to be the nuclear fraction. Both fractions were stored at
-20°C.
Luciferase reporter assay
Cells were plated overnight in 24-well plates (Corning) until 50% conﬂu-
ent, then transfected with 2 plasmids in a 1:1 ratio – a plasmid encodingMITF
and a plasmid encoding the ﬁreﬂy luciferase gene under the control of the
TYR promoter. Cells were harvested 48 hours post-transfection by incubating
with 100 μl Passive Lysis Buffer (Promega) for 30 minutes at 4°C on a rocking
platform. 20 μl of the lysate was mixedwith 50 μl of Luciferase Assay Reagent
(Promega) in a white 96-well plate (Corning), after which luminescence
was detected with a GloMax-Multi Microplate Multimode Reader (Promega)
luminometer.
Acknowledgements
This research was supported by A*STAR Singapore (KCN), Cancer Re-
search UK (CRUK) grant number C38302/A12981, through a CRUK Oxford
Centre Prize DPhil Studentship (HF), The China Scholarship Council (LL), a
Wellcome Trust Career Development Fellowship (095751/Z/11/Z) (P.F., S.P.),
the Structural Genomics Consortium (SK), Arthritis Research UK (MP/19200)
and The Rosetrees Trust (M456) (HK), The Research Fund of Iceland (ES),
the Ludwig Institute for Cancer Research (CRG, SA, GB) and the Kennedy
Trust Fund (RF). EEP is supported by MRC human genetics Unit programme











































































































































MEL-CHEMBIO-g48489) to fundHB, and L’Oreal-Melanoma Research Alliance
(401181). KLBB is supported by NIH grants NIH 98571, NIH 80728 and holds a
Canada Research Chair (Tier 1). We thank Katherine Dowsett for assistance
with the zebraﬁsh experiments. Mass spectrometry analysis was performed
in the TDI MS Laboratory led by Benedikt M. Kessler. Author Contribution
KCN, HF, LL, ZZ, HB and LV undertook all experiments; SK provided the kinase
inhibitor library; SP synthesized the peptide array; SA, GB and RF performed
and interpreted the proteomics analysis; RL provided technical support; HK
generated the osteoclasts; EEP, KLBB, PF, ES and CRG provided supervision
and funding; KCN and CRG conceived the study and wrote the manuscript.
The authors declare no competing ﬁnancial interests. Correspondence and
requests for materials should be sent to CRG (colin.goding@ludwig.ox.ac.uk)
1. Garraway LA, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival
oncogene amplified in malignant melanoma. Nature 436(7047):117-122.
2. Lister JA, et al. (2013)A conditional zebrafishMITFmutation revealsMITF levels are critical
for melanoma promotion versus regression in vivo. J. Invest. Dematol. 134(1):133-140.
3. Hodgkinson CA, et al. (1993) Mutations at the mouse microphthalmia locus are associated
with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. Cell 74(2):395-
404.
4. Widlund HR, et al. (2002) Beta-catenin-induced melanoma growth requires the downstream
target Microphthalmia-associated transcription factor. J. Cell. Biol. 158(6):1079-1087.
5. Carreira S, et al. (2005) Mitf cooperates with Rb1 and activates p21Cip1 expression to
regulate cell cycle progression. Nature 433(7027):764-769.
6. Carreira S, et al. (2006) Mitf regulation of Dia1 controls melanoma proliferation and
invasiveness. Genes Dev. 20(24):3426-3439.
7. Cheli Y, et al. (2011) Mitf is the key molecular switch between mouse or human melanoma
initiating cells and their differentiated progeny. Oncogene 30:2307-2318.
8. Hoek KS, et al. (2006)Metastatic potential of melanomas defined by specific gene expression
profiles with no BRAF signature. Pigment Cell Res. 19(4):290-302.
9. Hoek K & Goding CR (2010) Cancer stem cells versus phenotype switching in melanoma.
Pigment Cell Melanoma Res. 23:746-759.
10. Falletta P, et al. (2017) Translation reprogramming is an evolutionarily conserved driver of
phenotypic plasticity and therapeutic resistance in melanoma. Genes Dev.31:18-33.
11. Johannessen CM, et al. (2013) A melanocyte lineage program confers resistance to MAP
kinase pathway inhibition. Nature 504(7478):138-142.
12. Muller J, et al. (2014) Low MITF/AXL ratio predicts early resistance to multiple targeted
drugs in melanoma. Nat. Commun. 5:5712.
13. Dugo M, et al. (2015) A melanoma subtype with intrinsic resistance to BRAF inhibition
identified by receptor tyrosine kinases gene-driven classification. Oncotarget 6(7):5118-5133.
14. Konieczkowski DJ, et al. (2014) A melanoma cell state distinction influences sensitivity to
MAPK pathway inhibitors. Cancer Discov. 4(7):816-827.
15. Giuliano S, et al. (2010) Microphthalmia-associated transcription factor controls the DNA
damage response and a lineage-specific senescence program in melanomas. Cancer Res.
70(9):3813-3822.
16. Zhang T, et al. (2015) Mitf is a master regulator of the v-ATPase, forming a control module
for cellular homeostasis with v-ATPase and TORC1. J. Cell. Sci. 128(15):2938-2950.
17. Ploper D, et al. (2015) MITF drives endolysosomal biogenesis and potentiates Wnt signaling
in melanoma cells. Proc. Natl. Acad. Sci. USA 112:E420-429.
18. Haq R, et al. (2013) Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and
MITF. Cancer Cell 23(3):302-315.
19. Vazquez F, et al. (2013) PGC1alpha expression defines a subset of human melanoma
tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell
23(3):287-301.
20. Bharti K, Liu W, Csermely T, Bertuzzi S, & Arnheiter H (2008) Alternative promoter use
in eye development: the complex role and regulation of the transcription factor MITF.
Development 135(6):1169-1178.
21. Perera RM, et al. (2015) Transcriptional control of autophagy-lysosome function drives
pancreatic cancer metabolism. Nature 524(7565):361-365.
22. Miller AJ, Levy C, Davis IJ, Razin E, & Fisher DE (2005) Sumoylation of MITF and its
related family members TFE3 and TFEB. J. Biol.Chem. 280(1):146-155.
23. Murakami H & Arnheiter H (2005) Sumoylation modulates transcriptional activity of MITF
in a promoter-specific manner. Pigment Cell Res. 18(4):265-277.
24. Bertolotto C, et al. (2011) A SUMOylation-defective MITF germline mutation predisposes
to melanoma and renal carcinoma. Nature 480(7375):94-98.
25. Yokoyama S, et al. (2011) A novel recurrent mutation in MITF predisposes to familial and
sporadic melanoma. Nature 480(7375):99-103.
26. Price ER, et al. (1998) Lineage -specific signalling in melanocytes: c-Kit stimulation recruits
p300/CBP to Microphthalmia. J. Biol. Chem. 273:17983-17986.
27. Wu M, et al. (2000) c-Kit triggers dual phosphorylations, which couple activation and
degradation of the essential melanocyte factor Mi. Genes Dev. 14(3):301-312.
28. Xu W, et al. (2000) Regulation of microphthalmia-associated transcription factor MITF
protein levels by association with the ubiquitin-conjugating enzyme hUBC9. Exp. Cell. Res.
255(2):135-143.
29. Mansky KC, Sankar U, Han J, & Ostrowski MC (2002) Microphthalmia Transcription Factor
Is a Target of the p38 MAPK Pathway in Response to Receptor Activator of NF-kappa B
Ligand Signaling. J. Biol. Chem. 277(13):11077-11083.
30. Bronisz A, et al. (2006) Microphthalmia-associated transcription factor interactions with 14-
3-3 modulate differentiation of committed myeloid precursors. Bol. Biol. Cell 17(9):3897-
3906.
31. Martina JA & Puertollano R (2013) Rag GTPases mediate amino acid-dependent recruit-
ment of TFEB and MITF to lysosomes. J. Cell Biol. 200(4):475-491.
32. Takeda K, et al. (2000) Ser298 of MITF, a mutation site in Waardenburg syndrome type 2, is
a phosphorylation site with functional significance. Hum. Mol. Genet. 9(1):125-132.
33. Drewry DH, Willson TM, & Zuercher WJ (2014) Seeding collaborations to advance kinase
science with the GSK Published Kinase Inhibitor Set (PKIS). Curr Top Med Chem 14(3):340-
342.
34. Meijer L, et al. (2003) GSK-3-selective inhibitors derived from Tyrian purple indirubins.
Chem. Biol. 10(12):1255-1266.
35. Bennett DC (2015) Genetics of melanoma progression: the rise and fall of cell senescence.
Pigment Cell & Melanoma Res. 29(2):129-140.
36. Fedorenko IV, Gibney GT, Sondak VK, & Smalley KS (2015) Beyond BRAF: where next for
melanoma therapy? Brit. J. Cancer 112(2):217-226.
37. Vredeveld LC, et al. (2012) Abrogation of BRAFV600E-induced senescence by PI3K path-
way activation contributes to melanomagenesis. Genes Dev. 26(10):1055-1069.
38. Delmas V, et al. (2007) Beta-catenin induces immortalization of melanocytes by suppressing
p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev.
21(22):2923-2935.
39. Hemesath TJ, Price ER, Takemoto C, Badalian T, & Fisher DE (1998) MAP kinase links the
transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 391:298-301.
40. Frame S & Cohen P (2001) GSK3 takes centre stage more than 20 years after its discovery.
Bioch. J. 359(Pt 1):1-16.
41. Bensimon A, et al. (2010) ATM-dependent and -independent dynamics of the nuclear
phosphoproteome after DNA damage. Science Signal. 3(151):rs3.
42. Takebayashi K, et al. (1996) The recessive phenotype displayed by a dominant negative
microphthalmia-associated transcription factor mutant is a result of impaired nucleation
pote tial.Mol. Cell. Biol. 16(3):1203-1211.
43. Kutay U & Güttinger S (2005) Leucine-rich nuclear-export signals: born to be weak. Trends
Cell Biol. 15(3):121-124.
44. Fornerod M, Ohno M, Yoshida M, & Mattaj IW (1997) CRM1 is an export receptor for
leucine-rich nuclear export signals. Cell 90(6):1051-1060.
45. Kirli K, et al. (2015) A deep proteomics perspective on CRM1-mediated nuclear export and
nucleocytoplasmic partitioning. eLife 4, pii: e11466. doi: 10.7554/eLife.11466
46. Weis K (2003) Regulating access to the genome: nucleocytoplasmic transport throughout the
cell cycle. Cell 112(4):441-451.
47. Kalderon D, Roberts BL, RichardsonWD, & Smith AE (1984) A short amino acid sequence
able to specify nuclear location. Cell 39:499-509.
48. WenW,Meinkoth JL, Tsien RY, & Taylor SS (1995) Identification of a signal for rapid export
of proteins from the nucleus. Cell 82(3):463-473.
49. Takeda K, et al. (2002) Mitf-D, a newly identified isoform, expressed in the retinal pigment
epithelium and monocyte-lineage cells affected by Mitf mutations. Biochim. Biophys. Acta
1574(1):15-23.
50. Kaffman A, Rank NM, O'Neill EM, Huang LS, & O'Shea EK (1998) The receptor Msn5 ex-
ports the phosphorylated transcription factor Pho4 out of the nucleus.Nature 396(6710):482-
486.
51. Alt JR, Cleveland JL, HanninkM, &Diehl JA (2000) Phosphorylation-dependent regulation
of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev.
14(24):3102-3114.
52. Marsh Durban V, Deuker MM, Bosenberg MW, Phillips W, & McMahon M (2013) Differ-
ential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J.
Clin. Invest. 123(12):5104-5118.
53. Nogueira C, et al. (2010) Cooperative interactions of PTEN deficiency and RAS activation
in melanoma metastasis. Oncogene 29(47):6222-6232.
54. Dankort D, et al. (2009) Braf(V600E) cooperates with Pten loss to induce metastatic
melanoma. Nat. Genet.41(5):544-552.
55. Stambolic V &Woodgett JR (1994) Mitogen inactivation of glycogen synthase kinase-3 beta
in intact cells via serine 9 phosphorylation. Biochem. J.303 ( Pt 3):701-704.
56. Takeda K, et al. (2000) Induction of melanocyte-specific microphthalmia-associated tran-
scription factor by Wnt-3a. J. Biol. Chem. 275(19):14013-14016.
57. Dorsky RI, Raible DW, & Moon RT (2000) Direct regulation of nacre, a zebrafish MITF
homolog required for pigment cell formation, by the Wnt pathway. Genes Dev. 14(2):158-
162.
58. Rabbani P, et al. (2011) Coordinated activation of Wnt in epithelial and melanocyte stem
cells initiates pigmented hair regeneration. Cell 145(6):941-955.
59. Habib SJ, et al. (2013) A localized Wnt signal orients asymmetric stem cell division in vitro.
Science (New York, N.Y.) 339(6126):1445-1448.
60. Pogenberg V, et al. (2012) Restricted leucine zipper dimerization and specificity of DNA
recognition of the melanocyte master regulator MITF. Genes Dev. 26(23):2647-2658.
61. Grill C, et al. (2013) MITF mutations associated with pigment deficiency syndromes and
melanoma have different effects on protein function. Hum. Mol. Genet. 22(21):4357-4367.
62. Zeng Z, Johnson SL, Lister JA, & Patton EE (2015) Temperature-sensitive splicing of mitfa
by an intron mutation in zebrafish. Pigment Cell & Melanoma Res. 28(2):229-232.
63. Westerfield M (2000) The zebrafish book. A guide for the laboratory use of zebrafish (Danio





































































10 www.pnas.org --- --- Footline Author
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
